Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort

Schröder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Van Poppel, 2021, Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021, Eur Urol, 80, 703, 10.1016/j.eururo.2021.07.024 Draisma, 2009, Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context, J Natl Cancer Inst, 101, 374, 10.1093/jnci/djp001 Van Poppel, 2022, Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future, Nat Rev Urol, 19, 562, 10.1038/s41585-022-00638-6 Grönberg, 2015, Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study, Lancet Oncol, 16, 1667, 10.1016/S1470-2045(15)00361-7 Eklund, 2018, The Stockholm-3 (STHLM3) model can improve prostate cancer diagnostics in men aged 50–69 yr compared with current prostate cancer testing, Eur Urol Focus, 4, 707, 10.1016/j.euf.2016.10.009 Kroenig, 2016, Diagnostic accuracy of robot-guided, software based transperineal MRI/TRUS fusion biopsy of the prostate in a high risk population of previously biopsy negative men, Biomed Res Int, 2016, 2384894, 10.1155/2016/2384894 Iczkowski, 2021, The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma, Am J Surg Pathol, 45, 1007, 10.1097/PAS.0000000000001678 Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making, 26, 565, 10.1177/0272989X06295361 Nordström, 2021, Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial, Lancet Oncol, 22, 1240, 10.1016/S1470-2045(21)00348-X Eklund, 2021, MRI-targeted or standard biopsy in prostate cancer screening, N Engl J Med, 385, 908, 10.1056/NEJMoa2100852 Möller, 2019, The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort, Prostate Cancer Prostat Dis, 22, 137, 10.1038/s41391-018-0082-5 Grönberg, 2018, Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging, Eur Urol, 74, 722, 10.1016/j.eururo.2018.06.022 Tilki, 2023, A0067 – External validation of Stockholm3 in a retrospective German clinical cohort, Eur Urol, 83, S100, 10.1016/S0302-2838(23)00125-2 Nordström, 2015, Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer, Eur Urol, 68, 139, 10.1016/j.eururo.2014.08.010 Kim, 2020, Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study, BMC Med, 18, 95, 10.1186/s12916-020-01548-3 Punnen, 2018, Optimizing patient’s selection for prostate biopsy: a single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer, PLoS One, 13, e0201384, 10.1371/journal.pone.0201384